HCS PHARMA

About:

HCS Pharma is revolutionising drug discovery with a unique 3D cell technology, BIOMIMESYS®

Twitter/X: hcspharma

Top Investors: The Global Emerging Markets Group, Eurasante

Description:

HCS Pharma is a biotechnology company focused on in vitro R&D, specializing in high content (HCA) and high throughput (HCS) cell imaging screening. HCS Pharma sells products based on BIOMIMESYS® technology, and develops its own 3D cellular models in its proprietary BIOMIMESYS® extracellular matrix. BIOMIMESYS® 3D culture technology faithfully reproduces the natural microenvironment of cells in 3D, to ensure more predictive results from in vitro studies, to reduce the time and cost of R&D, and animal testing in pharmaceutical, nutraceutical and cosmetic companies.

Total Funding Amount:

22M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Loos, Nord-Pas-de-Calais, France

Founded Date:

2014-01-01

Contact Email:

welcome(AT)hcs-pharma.com

Founders:

Nathalie Maubon, Nathalie Maubon

Number of Employees:

1-10

Last Funding Date:

2022-03-01

IPO Status:

Private

Industries: